CD34 and glaucoma: Some studies are now expanding to central retinal vein occlusion (NCT03981549; using intravitreal autologous bone marrow CD34+ stem cell), disciform scar secondary to nAMD (NCT02903576; injecting hESC-RPE into the subretinal space) or other diseases, such as glaucoma and optic atrophy (Stem Cell Ophthalmology Treatment Study; SCOTS; NCT01920867 and NCT03011541).